Wai Yuen Tong Medicine Holdings (HKSE:00897) Debt-to-Equity : 0.74 (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Wai Yuen Tong Medicine Holdings Debt-to-Equity?

Wai Yuen Tong Medicine Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was HK$760 Mil. Wai Yuen Tong Medicine Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was HK$878 Mil. Wai Yuen Tong Medicine Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was HK$2,226 Mil. Wai Yuen Tong Medicine Holdings's debt to equity for the quarter that ended in Sep. 2023 was 0.74.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Wai Yuen Tong Medicine Holdings's Debt-to-Equity or its related term are showing as below:

HKSE:00897' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.21 Med: 0.37 Max: 1.13
Current: 0.74

During the past 13 years, the highest Debt-to-Equity Ratio of Wai Yuen Tong Medicine Holdings was 1.13. The lowest was 0.21. And the median was 0.37.

HKSE:00897's Debt-to-Equity is ranked worse than
77.43% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:00897: 0.74

Wai Yuen Tong Medicine Holdings Debt-to-Equity Historical Data

The historical data trend for Wai Yuen Tong Medicine Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wai Yuen Tong Medicine Holdings Debt-to-Equity Chart

Wai Yuen Tong Medicine Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.35

0.74

0.69

0.72

0.70

Wai Yuen Tong Medicine Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.75	0.72	0.83	0.70	0.74

Competitive Comparison of Wai Yuen Tong Medicine Holdings's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wai Yuen Tong Medicine Holdings's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Wai Yuen Tong Medicine Holdings's Debt-to-Equity falls into.

Wai Yuen Tong Medicine Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Wai Yuen Tong Medicine Holdings's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(614.39	+	1032.461)	/	2349.191
	=	0.70

Wai Yuen Tong Medicine Holdings's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(759.546	+	877.709)	/	2225.827
	=	0.74

Wai Yuen Tong Medicine Holdings (HKSE:00897) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Wai Yuen Tong Medicine Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Wai Yuen Tong Medicine Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Wai Yuen Tong Medicine Holdings (HKSE:00897) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wai Yuen Tong Medicine Holdings Ltd (HKSE:00897) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

39 Wang Kwong Road, Suite 3101, 31st Floor, Skyline Tower, Kowloon Bay, Kowloon, Hong Kong, HKG

Website

https://www.wyth.net

Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties in the agricultural produce market. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.

Executives

Wang On Group Limited	2501 Other
Tang Ching Ho	2501 Other
Yau Yuk Yin	2202 Interest of your spouse

Wai Yuen Tong Medicine Holdings (HKSE:00897) Headlines

No Headlines